Johan Vanhaecke

TL;DR: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the numberOf cardiovascular hospitalizations and the drugdid not cause safety problems.

TL;DR: Institutional Affiliations Chair Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA Task Force 1 Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland Clinic Foundation, Cleveland, Ohio, USA; Starlings R: University of Chicago, Chicago, Illinois,USA; Chan M: university of Alberta, Edmonton, Alberta, Canada ; Desai S: Inova Fairfax Hospital, Fairfax, Virginia, USA.

TL;DR: Elevated plasma levels of MDA-modified LDL suggest plaque instability and may be useful for the identification of patients with acute coronary syndromes and stable CAD.

TL;DR: Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotens in-converting enzyme inhibition.

TL;DR: One‐year graft and patient survival are better in adolescent transplant recipients (age 11–19 years) than in younger (age < 11’years) pediatric transplant recipients, but several groups found that long‐term outcomes in the adolescent age group are significantly worse than in young transplant recipients.